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MicroRNAs (miRNAs) are small, noncoding RNAs that can contrib-
ute to cancer development and progression by acting as oncogenes
or tumor suppressor genes. Recent studies have also linked differ-
ent sets of miRNAs to metastasis through either the promotion or
suppression of this malignant process. Interestingly, epigenetic
silencing of miRNAs with tumor suppressor features by CpG island
hypermethylation is also emerging as a common hallmark of
human tumors. Thus, we wondered whether there was a miRNA
hypermethylation profile characteristic of human metastasis. We
used a pharmacological and genomic approach to reveal this
aberrant epigenetic silencing program by treating lymph node
metastatic cancer cells with a DNA demethylating agent followed
by hybridization to an expression microarray. Among the miRNAs
that were reactivated upon drug treatment, miR-148a, miR-34b/c,
and miR-9 were found to undergo specific hypermethylation-
associated silencing in cancer cells compared with normal tissues.
The reintroduction of miR-148a and miR-34b/c in cancer cells with
epigenetic inactivation inhibited their motility, reduced tumor
growth, and inhibited metastasis formation in xenograft models,
with an associated down-regulation of the miRNA oncogenic
target genes, such as C-MYC, E2F3, CDK6, and TGIF2. Most impor-
tant, the involvement of miR-148a, miR-34b/c, and miR-9 hyper-
methylation in metastasis formation was also suggested in human
primary malignancies (n  207) because it was significantly asso-
ciated with the appearance of lymph node metastasis. Our findings
indicate that DNA methylation-associated silencing of tumor sup-
pressor miRNAs contributes to the development of human cancer
metastasis.
M icroRNAs (miRNAs) are small, noncoding RNAs, 22nucleotides long, that repress gene expression in a variety
of eukaryotic organisms (1, 2). In animals, these single-stranded
RNAs interact with specific target mRNAs through an almost
perfect complementarity with sequences located in the 3 UTR,
where they induce mRNA degradation or translational inhibi-
tion (1, 2). miRNAs play important roles in several cellular
processes, such as proliferation, differentiation, apoptosis, and
development, by simultaneously controlling the expression levels
of hundreds of genes (1, 2). In human cancer, recent studies have
shown that miRNA expression profiles differ between normal
tissues and derived tumors and between tumor types (3, 4).
miRNAs can act as oncogenes or tumor suppressors, exerting a
key function in tumorigenesis (5, 6). Recently, a new function
mediating tumor metastasis in breast cancer has been assigned
to miRNAs, by which this malignant step is promoted (7, 8) or
suppressed (9). However, the precise contribution of miRNAs to
human metastasis and the mechanism underlying their dysregu-
lation remain largely unexplored.
The metastatic process consists of sequential, interrelated
steps by which primary tumor cells acquire the capacity to invade
the adjacent tissue, enter the systemic circulation, translocate
through the vasculature, arrest in distant capillaries, extravasate
into the surrounding tissue parenchyma, and, finally, proliferate
from micrometastases into macroscopic secondary tumors (10,
11). The lymphatic route of metastasis is particularly relevant for
carcinomas, where regional lymph nodes are often the first
organs to develop metastasis and might serve as a potential
‘‘bridgehead’’ in further dissemination (12, 13). Metastasis is
responsible for 90% of deaths in patients with solid tumors (10,
11), so understanding its pathogenesis at the systemic, cellular,
and molecular levels has become one of the most ambitious goals
in cancer research (10, 11). The discovery of the contribution of
miRNAs to metastasis has given us great insight into the process.
On one hand, three metastasis-promoting miRNAs have been
described (7, 8): miR-10b promotes cell migration and invasion
through homeobox D10 inhibition (7), whereas miR-373 and
miR-520c cooperate in metastasis by suppressing CD44 (8). On
the other hand, miRNAs like miR-126 and miR-335 (9) can act
as metastasis suppressors, the latter by targeting oncogene SOX4
and tenascin C (9).
However, one question remains largely unanswered: what
are the defects leading to the imbalance of miRNAs in cancer
cells? Genetic alterations (14, 15) and failure of posttranscrip-
tional regulation might cause the dysregulation of subsets of
miRNAs, but epigenetic alterations also appear to be likely
culprits (16, 17). In classical tumor suppressor genes, promoter
CpG island hypermethylation occurs in genes involved in cell
adherence, invasion, and angiogenesis, such as cadherins,
tissue inhibitors of metalloproteinases, and thrombospondins
(18). For miRNAs, we and others have recently identified the
presence of CpG island methylation-associated silencing of
miRNAs with tumor suppressor features in human cancer
(19–22), such as miR-127 and miR-124a. Thus, aberrant
hypermethylation events in the regulatory regions of miRNAs
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might also play a role in the establishment of human metas-
tasis. Herein we present a pharmacological and genomic
unmasking of hypermethylated miRNAs, such as miR-148a,
miR-34b/c, and miR-9, that contribute in vitro and in vivo to the
formation of lymph node metastasis, one of the first steps in
the dissemination of human tumors.
Results and Discussion
Identification of miRNAs Undergoing Transcriptional Silencing in
Metastatic Cancer Cells by miRNA Expression Microarray Analysis
upon DNA-Demethylating Drug Treatment. To identify miRNAs
with putative DNA methylation-related inactivation involved
in metastasis, we followed the experimental algorithm shown
in Fig. 1A. First, we treated three representative human cancer
cell lines established from lymph node metastasis from colon
(SW620), melanoma (IGR37), and head and neck (SIHN-
011B) with the DNA methylation inhibitor 5-aza-2-
deoxycytidine. To measure miRNA levels, total RNA was
extracted before and after treatment with the DNA demethy-
lating drug in each case and profiled by using our previously
validated miRNA platform (23). Unsupervised principal com-
ponent analysis of normalized and filtered datasets showed
clear separation between various classes (SW620, SIHN-011B,
and IGR37 untreated and treated cell lines), showing high
similarity among samples that belong to the same group. Our
pharmacological screening revealed that, considering all three
metastatic cancer cell lines, 57 of 389 (15%) different human
miRNAs printed on the microarray had minimal basal expres-
sion in the untreated cells and 2-fold up-regulation upon use
of 5-aza-2-deoxycytidine [supporting information (SI) Table
S1 and Table S2]. Of these 57 significantly up-regulated
miRNAs, 27 (47%) were embedded in a canonical CpG island
(Table S2). miR-126 and miR-126*, which originated from the
same genomic locus, were the only two miRNAs commonly
up-regulated upon administering the DNA methylation inhib-
itor in SW620, IGR37, and SIHN-011B cells. Interestingly,
miR-126 is one of the first miRNAs for which a role as a
metastasis suppressor has been proposed (9).
CpG Island DNA Methylation Analysis and Expression Studies of
Candidate Metastasis Suppressor miRNAs. To demonstrate the pres-
ence of CpG island methylation in these 27 up-regulated miR-
NAs, we undertook bisulfite genomic sequencing analyses of
multiple clones in the metastatic cancer cell from which the
miRNA expression microarray data were obtained. We found
dense CpG island hypermethylation in 16 (59%) of the described
miRNAs (Fig. 1 A and Table S2). We wanted to focus on the
cancer-specific DNA methylation changes, so we used bisulfite
genomic sequencing to analyze the DNA methylation status of
these 16 miRNAs in normal tissues (n  32), including colorectal
mucosa, lymphocytes, and skin, to exclude tissue-specific DNA
methylation patterns. The expression of many miRNAs is tightly
regulated according to cell type (1, 2), so it was not surprising to
observe that 11 (65%) of the miRNAs were also densely
methylated in normal tissues (Fig. 1 A, Table S2, and Fig. S1).
The previously mentioned miR-126 was one of these. However,
and most importantly, miR148a, miR-34b/c, miR-9-1, miR-9-2,
and miR-9-3 were always unmethylated in all normal tissues
studied (Fig. 1 A and B, Table S2, and Fig. S2). The DNA
methylation results were also confirmed by using methylation-
specific PCR (Fig. 1C). Thus, the CpG island hypermethylation
of these miRNAs was cancer-specific.
To demonstrate the transcriptional silencing of these miRNAs
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Fig. 1. Pharmacological epigenomic unmasking of cancer-specific hypermethylated miRNAs in metastasis cancer cells. (A) Schematic strategy used to identify
DNA methylation-associated repression of miRNAs in metastatic cancer cell lines. (B) Bisulfite genomic sequencing analyses of the miR-34b/c cluster, miR-9-3, and
miR-148a CpG islands in normal tissues and metastatic cell lines. Eight single clones are represented for each sample. The CpG island is depicted, and each vertical
bar illustrates a single CpG. Black and white squares represent methylated and unmethylated CpG, respectively. NL, normal lymphocytes; NC, normal colon; NS,
normal skin. These miRNAs show cancer-specific CpG island hypermethylation. (C) Methylation-specific PCR analyses of miR-148a, miR-34b/c, and miR-9-3. Normal
lymphocytes (NL) and in vitro-methylated DNA (IVD) are shown as positive controls for the unmethylated and methylated sequences, respectively. (D) Expression
analyses of mature miRNAs by qRT-PCR in methylated metastatic cell lines in untreated cells and upon treatment with the DNA demethylating agent
5-aza-2-deoxycytidine (AZA). The use of the DNA methylation inhibitor restores miRNA expression.











island hypermethylation, we measured mature miRNA levels by
quantitative RT-PCR (qRT-PCR). The expression of miR148a,
miR-34b, miR-34c, and miR-9 transcripts was not detectable in
those cells showing CpG island methylation of the corresponding
miRNA (Fig. 1D). Most important, a restoration of miRNA
expression was observed upon treatment with the DNA dem-
ethylating agent (Fig. 1D). Thus, our data obtained from the
miRNA microarray and the DNA methylation assays suggested
that miR148a, miR-34b, miR-34c, and miR-9 transcripts were
induced from their own CpG island-associated promoter after
treatment with the DNA methylation inhibitor. These results
were confirmed by the determination of the potential transcrip-
tion start sites for the primary transcripts of these miRNAs after
5-aza-2-deoxycytidine treatment using 5 RACE (24) in the
corresponding metastatic cell lines. We were able to identify a
start site for each miRNA transcript (miR-9-1, miR-9-2, miR-
9-3, miR-148, and miR-134b/c) within the described correspond-
ing CpG island (Fig. S3). Interestingly, miR-9-3 and miR34b/c
might also be part of the larger transcripts CR612213 and
BC021736, respectively (http://genome.ucsc.edu/cgi-bin/
hgGateway) (25), but those start sites are located in CpG poor
sequences that were mostly unmethylated in both normal and
transformed cells (Fig. S4). In the case of miR-34b/c, a recent
report shows that a promoter region for this miRNA overlaps
with the described CpG island and that treatment with a DNA
demethylating agent induces the expression of miR-34b/c but not
of BC021736 (26).
Most important, we analyzed alterations in chromatin struc-
ture in the CpG islands where we mapped the putative tran-
scription start sites of miR-9-1, miR-9-2, miR-9-3, miR-148, and
miR-34b/c by chromatin immunoprecipitation. We observed
that in the corresponding metastatic cancer cell lines the five
described hypermethylated miRNA CpG islands were depleted
in histone marks associated with open chromatin structure and
active transcription, such as acetylated histone H4 and trimethy-
lated lysine-4 of histone H3 (Fig. S5). Remarkably, these CpG
islands showed a pronounced increase in both active marks upon
treatment with the DNA demethylating agent (Fig. S5). Identical
chromatin setting has been described for the hypermethylated
CpG islands of miR-127 and miR-34b/c (19, 26). Treatment with
an inhibitor of histone deacetylases (trichostatin A) as a single
agent did not achieve restoration of miRNA expression or
miRNA CpG island DNA hypomethylation (Fig. S6).
Hypermethylated miRNAs Show Metastasis Tumor Suppressor Fea-
tures in Vitro and in Vivo. Once we had observed the specific CpG
island hypermethylation-associated silencing of miR-148a, miR-
34b/c, miR-9-1, miR-9-2, and miR-9-3 in metastatic cancer cells,
we sought to demonstrate that the epigenetic inactivation of
these miRNAs contributed to metastasis formation. We took
two approaches: in vitro and in vivo. For the former, we stably
transfected the metastatic carcinoma cell line SIHN-011B, hy-
permethylated and silenced for miR-148a and miR-34b/c, with
expression vectors containing the flanking regions of the mature
miR-148a or miR-34b/c. The efficiency of the transfection was
tested by measuring the mature miRNA levels by qRT-PCR
(data not shown). We then measured the migration capability of
the transfected control short hairpin RNA (c-shRNA) vector
(Ambion) compared with the miRNA transfected metastatic
SIHN-011B cells using the wound-healing assay (27). miR-148a
and miR-34b/c transfected SIHN-011B cells had a significantly
lower capability of migration than did c-shRNA vector cells (P 
0.0001 in both cases) (Fig. 2A). For the in vivo approach, we used
tumor and metastasis formation assays in nude mice. Three
million SIHN-011B cells transfected with the c-shRNA vector,
miR-148a, or miR-34b/c were s.c. injected into nude mice, and
the tumor progression was studied over time. Both miRNA
transfected cell lines showed less tumor growth than seen with
c-shRNA vector transfected cells (Fig. 2B). Thirty days after
injection, all mice were killed and tumor weights were measured.
Again, these were significantly lower when arising from miR-
transfected cells than in the tumors originating from c-shRNA
vector cells (Fig. 2B). Most importantly, the inhibitory migration
and invasion activities of miR-148a and miR-34b/c were also
measured in athymic mice via tail-vein injection. Whereas
metastatic nodules developed in the lung over a period of 6–8
weeks after injection in the c-shRNA vector transfected SIHN-
011B cells (Fig. 2C), the metastasis events were not observed
with miR-148a or miR-34b/c transfected SIHN-011B cells in the
same period (Fig. 2C). These findings are evidence of the role of
miR-148a and miR-34b/c as suppressors of tumor dissemination.
Our data also corroborate the findings of recent studies
showing that miR-34 activation recapitulates tumor suppressor
events associated with p53 activity (28, 29) and that the down-
regulation of miR-148a, miR-9-2, and miR-34 is part of a unique
20-miRNA metastasis signature in liver tumors (30). The mech-
anisms underlying the inactivation of these miRNAs in human
tumors were mostly unknown, and our results now indicate that
CpG island hypermethylation is a likely molecular lesion respon-














































































































































Fig. 2. miR-148a and miR-34b/c suppress tumor invasion and dissemination
in vitro and in vivo. (A) Wound-healing assay. (Upper) The relative invasion of
c-shRNA cells compared with miRNA transfected cells after 16 h. (Lower)
Illustrative examples of the wound-healing assay in the c-shRNA and miRNA
transfected metastatic cell lines at 0 h and 16 h. Green and red lines represent
the initial and final leading edges of the invasion front, respectively. miR-148a
and miR-34b/c transfected cells show minor invasion capability. (B) Effects of
miRNA transfection on in vivo growth of metastatic SIHN-011B cells xe-
nografted into nude mice. (Left) Tumor volume was monitored over time, and
tumor weight was measured at the end of the experiment. (Right) Represen-
tative large tumors on the right flank (c-shRNA cells) and the small tumor on
the opposite flank, corresponding to miR-34b/c or miR-148a transfected cells.
Examples of the resected tumors are also shown. (C) Metastatic SIHN-011B
cancer cells with stable transfection of miR-148a, miR-34b/c, or a control vector
were transplanted into athymic nude mice by tail-vein injection. A graphical
representation of the number of lung metastases observed and illustrative
examples are shown.
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miR-148a and miR-34b/c Epigenetic Silencing Mediates the Activation
of Oncogenic and Metastasis Target Genes. To determine whether
the epigenetic silencing of miR-148a and miR-34b/c had func-
tional cancer relevance to overcome their putative metastasis
tumor suppressor function, we examined its effect on the regu-
lation of presumed target genes with oncogenic and metastatic
capacity. Using computational prediction for miR-34b/c target
genes, we observed that C-MYC, CDK6, and E2F3 were excel-
lent potential targets, whereas for miR-148a the TGIF2 gene was
one of the best candidates. Several lines of evidence relate the
described genes to metastasis potential, such as the finding that
metastasis-associated protein 1 (MTA1) is an essential down-
stream effector of the C-MYC oncoprotein (31), CDK6 is
involved in cell-cycle progression and differentiation (32), and
TGIF2 is overexpressed and amplified in aggressive ovarian
tumors (33). Using Western blot analyses for C-MYC, CDK6,
E2F3, and TGIF2, we observed that, whereas the untreated
metastatic cancer cell line SIHN-011B with miR-148a and
miR-34b/c methylation-associated silencing strongly expressed
the four proteins, the cells treated with the DNA demethylating
agent were down-regulated (Fig. 3A). To further confirm these
putative miRNA targets, SIHN-011B cells were transfected with
miR-148a and miR-34b/c precursor molecules, which are de-
signed to mimic endogenous miRs. We observed that overex-
pression of miR-148a induced a reduction of TGIF2 protein
levels (Fig. 3B). For miR-34b/c, miR-34b transfection decreased
CDK6 and C-MYC protein levels, whereas miR-34c transfection
induced the down-regulation of E2F3 protein levels (Fig. 3B).
These latter results relate to the different predicted targeting
scores of each miR-34b and miR-34c for the corresponding
proteins, as has also been recently described in ovarian cancer
cells (34).
Most importantly, a functional link was established by perform-
ing a luciferase reporter assay with vectors containing the C-MYC,
CDK6, E2F3, and TGIF2 WT putative 3 UTR target sites and
corresponding mutant forms (MUT) (Fig. S7). The luciferase
activities of miR-148a and miR-34b/c nonexpressing SIHN-011B
cells transfected with the WT and mutant vectors for the four
putative target proteins showed no measurable differences (Fig.
3C). However, when we cotransfected miR-148a, luciferase activity
of SIHN-011B TGIF2-WT-transfected cells was significantly lower
than with TGIF2-MUT (P  0.012; Fig. 3C). A similar pattern was
encountered for miR-34b/c: upon cotransfection of miR-34b, the
luciferase activity of C-MYC- and CDK6-WT-transfected cells was
significantly lower than that of the mutant forms (P  0.0001; Fig.
3C), whereas cotransfection of miR-34c caused a significant reduc-
tion of luciferase activity in E2F3-WT-transfected cells in compar-
ison to E2F3-MUT (P  0.0001; Fig. 3C). These findings suggest
that DNA methylation-associated silencing of miR-148a and miR-
34b/c in metastatic cancer cells prevents the down-regulation of the
corresponding miR targets, such as the oncoproteins C-MYC,
CDK6, E2F3, and TGIF2, and stimulates the progression and
dissemination of the tumor.
Hypermethylated miRNAs in Human Primary Malignancies Are Asso-
ciated with Metastasis Development. The presence of CpG island
hypermethylation of miR-148, miR-34b/c, and the miR-9 family
was not a specific feature of the cancer cell lines or an in vitro
phenomenon. We analyzed a comprehensive collection of hu-
man primary tumor samples (n  278) from the most common
tumor types, such as colon, lung, breast, and head and neck
carcinomas and melanomas, and frequently observed hyper-
methylation in the described miRNA metastasis tumor suppres-
sors (Fig. 4A and Table S3). Hypermethylation of the miRNAs
was absent from the corresponding normal tissue counterparts
(n  32). We subsequently tested whether the observed in vitro
loss of targeting oncoproteins mediated by miRNA methylation-
associated silencing was also observed in human primary tumors.
For this purpose, we studied the DNA methylation status of
miR34b/c in human lung carcinomas and melanomas (n  66) in
relation to the expression of C-MYC and CDK6, two of the
miRNA targets we had characterized in cell culture. Remark-
ably, the immunostaining analyses of C-MYC and CDK6 ex-
pression in the primary tumors patients showed that miR-34b/c
hypermethylation was associated with strong expression of C-
MYC and CDK6 (Pearson’s 2 test; P  0.0001 and P  0.040,
respectively; Table S3). Illustrative examples are shown in Fig.
4B. These data indicate that these two oncogenes are also
targeted by miR-34b/c in vivo and that epigenetic silencing of
miR-34b/c leads to their up-regulation in cancer patients.
However, the most compelling data concerning the role of
miR-148, miR-34b/c, and miR-9 epigenetic silencing in tumor
dissemination from the original location of the malignancy was
obtained when the miRNA hypermethylation status was deter-
mined with respect to the existence or not of lymph node
metastasis in the 207 tumors for which data were available (Table
S4). The presence of miR-34b/c, miR-148, and miR-9-3 CpG
island hypermethylation in the primary tumor was significantly
associated with those tumors that were positive for metastatic
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Fig. 3. miR-148a and miR-34b/c target and down-regulate cancer progression
and metastasis-related target genes. (A) Protein expression analysis by Western
blot for TGIF2, C-MYC, CDK6, and E2F3 in untreated and 5-aza-2-deoxycytidine-
treated SIHN-011B cells. The DNA demethylating agent induces down-regulation
of the oncoproteins. (B) Transfection of metastatic SIHN-011B cells with the
miR-148a, miR-34b, and miR-34c precursor molecules also causes a reduction in
the protein levels measured. (C) Interaction between the miRNAs and the 3 UTR
of the target genes. Luciferase assays of SIHN-011B cancer cells, transfected with
firefly luciferase constructs containing WT or mutant (MUT) target sites, and
cotransfected with negative control (N/C) or the corresponding precursor of
miRNA (miR-148a, miR-34b, or miR-34c) are shown.











test; P  0.002, P  0.019, and P  0.0001, respectively) (Fig. 4C
and Table S4), which highlights the importance of the in vivo role
of miRNA epigenetic silencing in metastasis formation.
Our findings not only reinforce the concept that CpG island
hypermethylation-mediated silencing of miRNAs with tumor
suppressor features contribute to human cancer, but also show
that particular DNA methylation signatures of miRNAs are
associated with the metastatic behavior of tumors. The demon-
stration that the epigenetic silencing of miRNAs, and their
associated loss of regulation of oncogenic target genes, is one
factor that contributes to metastasis formation in cell cultures;
xenograft tumor models and primary malignancies might also
have important clinical and therapeutic consequences. One
application could be the use of miRNA methylation markers to
predict tumor prognosis and metastatic behavior. Most impor-
tantly of all, it might provide a mechanistic and molecular basis
for a new therapeutic use for pharmacological compounds with
DNA demethylating activity in the treatment of cancer patients
with metastatic disease.
Materials and Methods
Human Metastatic Cancer Cell Lines. Several human cancer cell lines derived
from lymph node metastasis were acquired for our study: SW620 (colorectal
cancer) (American Type Culture Collection), IGR37 (melanoma) (German Col-
lection of Microorganisms and Cell Culture), and SIHN-011B (head and neck
cancer). The cell lines were treated with 1 M 5-aza-2-deoxycytidine (Sigma)
for 48 h (35). The primary tumor samples (n  278) and corresponding normal
tissues (n  32) from various tissue types were obtained under the approval of
the respective ethics committees.
RNA Isolation and miRNA Expression Analysis. Total RNA was isolated from
SW620, IGR37, and SIHN-011B cells, before and after 5-aza-2-deoxycytidine
treatment, by TRIzol extraction (Invitrogen). miRNA microarray profiling was
conducted as described (23). Details are provided in SI Materials and Methods.
DNA Methylation Analyses. The miRNA sequences were analyzed by using
miRBase (http://microrna.sanger.ac.uk/) and the University of California at
Santa Cruz Human Genome Browser (http://genome.cse.ucsc.edu). The CpG
Island Searcher Program (36) was used to determine which miRNAs were
embedded in a CpG island, because it has been predicted that 90% of the
human miRNA promoters are located 1,000 bp upstream of the mature miRNA
(37). DNA methylation status was established by PCR analysis of bisulfite-
modified genomic DNA, which induces chemical conversion of unmethylated,
but not methylated, cytosine to uracil. Details are provided in SI Materials and
Methods.
Quantification of miRNAs with Real-Time PCR. TaqMan miRNA assays were used
to quantify the level of mature miRNAs as described previously (38). Details are
provided in SI Materials and Methods.
RACE. RACE was developed as previously described (24). Details are provided
in SI Materials and Methods.
Chromatin Immunoprecipitation Assay. Standard chromatin immunoprecipi-
tation assays were developed as previously described (20). Details are provided
in SI Materials and Methods.
Stable Transfection of miRNAs. Cells were transfected with pSILENCER/TM
4.1-CMV Expression Vector (Ambion) containing the flanking regions of the
mature miRNAs (miR-148a and miR-34b/c). The primers used are described in
Table S5. Cells were selected with puromycin 48 h after transfection and then
diluted to perform clonal selection. The mature miRNA expression in the
selected clones was assessed by qRT-PCR as described above.
Wound-Healing Assay. Transfected cells (miR-148a and miR-34b/c) were grown
to confluence and wounded by dragging a 1-ml pipette tip through the
monolayer. Cells were washed to remove cellular debris and allowed to
migrate for 16 h. Images were taken at 0 and 16 h after wounding under a
DMI6000 inverted microscope. The relative surface traveled by the leading
edge was assessed by using LAS AF 6000 1.8.0 software. Five replicates each of
two independent experiments were performed.
Mouse Xenograft and Metastasis Models. Four- to 5-week-old male athymic
nu/nu mice (Charles River) were used in this study. Details are provided in SI
Materials and Methods.
Expression Analyses of miRNA Target Genes by Western Blot and Immunohis-
tochemistry. Information of base pairing comparison among miR-34b, miR-
34c, and miR-148a and their targets sites in the 3 UTR of c-MYC, E2F3, CDK6,
and TGIF2 mRNA is available at Targetscan (www.targetscan.org/). Western
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Fig. 4. The role of miRNA hypermethylation in the metastatic behavior of human primary tumors. (A) Methylation-specific PCR analyses for miR-148a,
miR-34b/c, miR-9-1, miR-9-2, and miR-9-3 in primary human tumors derived from different tissues. The presence of a band under the U or M lanes indicates
unmethylated or methylated sequences, respectively. Normal lymphocytes (NL) and in vitro methylated DNA (IVD) are shown as positive controls for the
unmethylated and methylated sequences, respectively. (B) Association between miRNA methylation and up-regulation of their corresponding oncoprotein
targets in primary tumors. Illustrative immunohistochemical examples demonstrate that C-MYC and CDK6 overexpression is associated with miR-34b/c
hypermethylation in lung tumors and melanomas, respectively. (C) Graphical representation of the distribution of miR-9, miR-34b/c, and miR-148a CpG island
hypermethylation in primary tumors according to the presence or absence of lymph node metastasis. The presence of hypermethylation of the miRNAs is
significantly associated with the existence of metastasis in human malignancies.
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Transfection with miR-34b, miR-34c, and miR-148a Precursor Molecules. miRNA
precursor molecules and negative control miRNA were purchased from Am-
bion. Experiments involving transient transfections of miRNAs were done
using oligofectamine (Invitrogen) and 100 nmol/liter RNA duplexes. The cells
were collected 48 h and 72 h after transfection, and the expression of c-MYC,
E2F3, CDK6, and TGIF2 was analyzed by Western blot.
Luciferase Reporter Assay. Luciferase constructs were made by ligating
oligonucleotides containing the WT or mutant putative target site of the
C-MYC, E2F3, CDK6, and TGIF2 3 UTR into the multicloning site of the
p-MIR Reporter Luciferase vector (Ambion). Details are provided in SI
Materials and Methods.
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